ES552368A0 - Un metodo para preparar un hibrido de anticuerpo - Google Patents

Un metodo para preparar un hibrido de anticuerpo

Info

Publication number
ES552368A0
ES552368A0 ES552368A ES552368A ES552368A0 ES 552368 A0 ES552368 A0 ES 552368A0 ES 552368 A ES552368 A ES 552368A ES 552368 A ES552368 A ES 552368A ES 552368 A0 ES552368 A0 ES 552368A0
Authority
ES
Spain
Prior art keywords
preparing
antibody hybrid
antibody
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES552368A
Other languages
English (en)
Other versions
ES8704734A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Royalty Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of ES8704734A1 publication Critical patent/ES8704734A1/es
Publication of ES552368A0 publication Critical patent/ES552368A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES552368A 1985-02-25 1986-02-25 Un metodo para preparar un hibrido de anticuerpo Expired ES8704734A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/705,271 US4698420A (en) 1985-02-25 1985-02-25 Antibody hybrid molecules and process for their preparation

Publications (2)

Publication Number Publication Date
ES8704734A1 ES8704734A1 (es) 1987-04-16
ES552368A0 true ES552368A0 (es) 1987-04-16

Family

ID=24832743

Family Applications (1)

Application Number Title Priority Date Filing Date
ES552368A Expired ES8704734A1 (es) 1985-02-25 1986-02-25 Un metodo para preparar un hibrido de anticuerpo

Country Status (7)

Country Link
US (1) US4698420A (es)
EP (1) EP0193161A3 (es)
JP (1) JPS61227532A (es)
AU (1) AU579058B2 (es)
CA (1) CA1239355A (es)
ES (1) ES8704734A1 (es)
NZ (1) NZ215288A (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202252A (en) * 1982-03-05 1993-04-13 Houston Biotechnology Inc. Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
US4863729A (en) * 1984-06-20 1989-09-05 Linus Pauling Institute Of Science And Medicine Method for preparing a macromolecular monoclonal antibody composition
AU587658B2 (en) * 1985-10-10 1989-08-24 Access Pharmaceuticals Australia Pty Limited Oral delivery of biologically active substances bound to vitamin b12, or analogues thereof
US5055561A (en) * 1985-11-19 1991-10-08 The Johns Hopkins University Protein label and drug delivery system
US5616122A (en) * 1986-11-04 1997-04-01 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) * 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5447837A (en) * 1987-08-05 1995-09-05 Calypte, Inc. Multi-immunoassay diagnostic system for antigens or antibodies or both
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
EP0436664B1 (en) * 1988-09-30 1994-11-09 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
CA2075927A1 (en) * 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
US5212075A (en) * 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US20030143638A1 (en) * 2000-04-07 2003-07-31 Mahito Hirai Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
SE0201655D0 (sv) * 2002-05-31 2002-05-31 Amersham Biosciences Ab A method of electrophoresis
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR20100107501A (ko) * 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
EP2270506A3 (en) * 2009-07-02 2011-03-09 Amic AB Amplified labeled conjugate for use in immunoassays
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
PL2814829T3 (pl) 2012-02-13 2017-06-30 Bristol-Myers Squibb Company Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
CN114137203A (zh) * 2021-10-21 2022-03-04 广州万孚生物技术股份有限公司 抗原与碱性磷酸酶结合物的制备方法
US20250282776A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Bicyclic TLR7 Agonists and Uses Thereof
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903262A (en) * 1972-03-13 1975-09-02 Cutter Lab Pharmaceutical compositions comprising intravenously injectable modified serum globulin, its production and use
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
US4350236A (en) * 1980-12-08 1982-09-21 Ford Aerospace & Communications Corp. Electromagnetic clutch assembly
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
JPS59116229A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
SE8302758L (sv) * 1983-05-17 1984-11-18 Pharmacia Ab Sett for uppspjelkning av disulfidbindningar och derigenom erhallen forening
EP0146050B1 (en) * 1983-12-16 1990-07-04 Denis M. Callewaert Site selective plasminogen activator and method of making and using same

Also Published As

Publication number Publication date
AU5402786A (en) 1986-08-28
US4698420A (en) 1987-10-06
NZ215288A (en) 1989-08-29
ES8704734A1 (es) 1987-04-16
JPS61227532A (ja) 1986-10-09
CA1239355A (en) 1988-07-19
EP0193161A3 (en) 1988-09-14
EP0193161A2 (en) 1986-09-03
AU579058B2 (en) 1988-11-10

Similar Documents

Publication Publication Date Title
ES547326A0 (es) Un metodo para preparar esterol-liposomas
ES554969A0 (es) Un procedimiento para preparar un complejo de inmunogeno
ES544968A0 (es) Un metodo para preparar un gel de silice-titania
ES552067A0 (es) Metodo para producir un preparado de etoposido
ES549633A0 (es) Un metodo para preparar un sistema de anticuerpo inmoviliza-do
ES557006A0 (es) Un metodo para preparar 6-hidroxi-2-acetilnaftaleno
ES557183A0 (es) Un metodo para preparar derivados de cefem
ES545386A0 (es) Un procedimiento para preparar un organotitanato
ES523419A0 (es) Un metodo para preparar derivados de 4-hidroxi-2-quinolona
ES551064A0 (es) Un metodo para preparar derivados de cefem
ES554206A0 (es) Un metodo para producir anticuerpos monoclonales
ES530017A0 (es) Un metodo para preparar derivados de 3-metilflavona
ES544862A0 (es) Un metodo para preparar un compuesto de morfolinol
ES557082A0 (es) Un procedimiento para producir un anticuerpo monoclonal
ES550466A0 (es) Un metodo para preparar derivados de 9-bencilpurina
ES535381A0 (es) Un metodo para preparar un derivado de azuleno
ES529181A0 (es) Un procedimiento para preparar un unguento oleoso a base de butirato-propionato de hidrocortisona
ES547458A0 (es) Un procedimiento para preparar derivados de piridiloxi
ES527705A0 (es) Un metodo para preparar derivados de fenotiazina
ES555741A0 (es) Un metodo para producir anticuerpos monoclonales humanos
ES552846A0 (es) Un metodo para producir interleuquina-2
AR241134A1 (es) Un procedimiento para preparar w-lactamas
ES557568A0 (es) Un procedimiento para preparar etil-alfa-(1-carboxi-etil)-ami-no-gamma-fenilbutirato
ES551424A0 (es) Un metodo para producir un interferon-gamma
ES554201A0 (es) Un procedimiento para preparar etanobenzazepinas

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970203